James W. Forsythe, MD, HMD, a board certified oncologist and homeopathic physician who has been in private practice in Reno, Nevada for 30 years in concert with AMARC Inc., and Garnett-McKeen Laboratories, Inc. embarked on a nine month outcome based study with Poly-MVA beginning in January 2004.

A total of 106 Stage IV adult cancer patients were included with a predominance of lung, prostate, breast, and colorectal cancers. The study continues with more patients added monthly.

Patients were given the option of a food supplement Poly-MVA, given with conventional chemotherapy or hormonal therapy or given alone.

A subset of patients also took Poly-MVA intravenously before going on oral Poly-MVA.

The overall response rate (ORR) which includes both partial and complete remission was 77% with prostate cancer, the best responder of 71%. Early deaths, discontinuations and too early cases were eliminated. The study continues to accrue data.

According to the Patent holder of the product, Palladium Lipoic Acid (PLA) acts by transferring electron charge from membrane fatty acids to DNA and mitochondria. Approximately a quarter volt of energy is utilized by the mitochondria, of normal cells, to combine with oxygen to form water in coupled reactions to produce energy (ATP) for normal growth and healing.

In anaerobic or severely hypoxic cell systems, however, such as in certain malignant tumors and protozoa, the electron energy cannot transfer to mitochondrial oxygen. Instead, a sequence of ionization begins in the cell membrane and in the mitochondrial membrane. These ionization reactions begin with membrane blebbing and mature into a cascade of reactions, known collectively as apoptosis, in which mitochondrial proteins are released, facilitating the activation of cell destructive enzymes. These reactions lead to the eventual death of the anaerobic or hypoxic (cancer) cell and provide a theoretical model for treatment studies.

Over 800 physicians who use Poly-MVA cannot be wrong. Dr. James Forsythe, Board Certified Oncologist, recently presented his latest 125 case study of stage 4 cancer patients with a 77 percent response rate using Poly- MVA. Non-Hodgkin's Lymphoma, Ovarian, Brain, Pancreatic, Breast, Multiple Myeloma, Leukemia and Lung cancers, many with wide metastasis responded. A 23 percent FULL REVERSAL statistic is unheard of in these types of cancers. Add to that 54 percent who had partial remissions and improvement and you have a phenomenon in the making. All of this has been accomplished with an average of six months of treatment. In summary, Dr. Forsythe reported: a 77% positive response rate in terminal patients!

Animal studies also show promising results for Poly-MVA as a valuable nutritional support anti- ischemia product when stroke has occurred. Studies are available.

Many medical practitioners nationwide already assist their many cancer and stroke patients with this safe, easily tolerated non-toxic discovery. We need your help to get the word out to more practitioners and patients. If practitioners are interested in doing more research we will work with them to get this research done.